Cartesian Therapeutics/$RNAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Ticker
$RNAC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
66
ISIN
US8162123025
RNAC Metrics
BasicAdvanced
$325M
-
-$1.73
-
-
Price and volume
Market cap
$325M
52-week high
$24.30
52-week low
$8.46
Average daily volume
75K
Financial strength
Current ratio
12.343
Quick ratio
12.148
Long term debt to equity
-47.556
Total debt to equity
-64.556
Profitability
EBITDA (TTM)
-41.935
Gross margin (TTM)
-46.43%
Net profit margin (TTM)
-112.11%
Operating margin (TTM)
-129.81%
Effective tax rate (TTM)
-0.75%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-7.50%
Return on equity (TTM)
55.29%
Valuation
Price to revenue (TTM)
8.213
Price to book
-14.91
Price to tangible book (TTM)
-1.47
Price to free cash flow (TTM)
-6.942
Free cash flow yield (TTM)
-14.41%
Free cash flow per share (TTM)
-180.50%
Growth
Revenue change (TTM)
31.91%
Earnings per share change (TTM)
-96.90%
What the Analysts think about RNAC
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
Bulls say / Bears say
Analysts have set an average price target of $42.86 for Cartesian Therapeutics, indicating potential upside from the current trading price. (etfdailynews.com)
Institutional investors, such as FMR LLC, have significantly increased their holdings in Cartesian Therapeutics, suggesting confidence in the company's future prospects. (etfdailynews.com)
The company has received a consensus 'Moderate Buy' rating from analysts, reflecting positive sentiment towards its stock. (americanbankingnews.com)
Cartesian Therapeutics reported a Q3 loss of $0.69 per share, missing revenue estimates and indicating financial challenges. (nasdaq.com)
The company's stock has experienced significant volatility, with a 52-week range between $11.66 and $42.60, which may concern risk-averse investors. (finance.yahoo.com)
JPMorgan Chase & Co. reduced its holdings in Cartesian Therapeutics by 11.1% in the fourth quarter, potentially signaling decreased confidence from major institutional investors. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RNAC Financial Performance
Revenues and expenses
RNAC Earnings Performance
Company profitability
RNAC News
AllArticlesVideos
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewsWire·1 month ago
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewsWire·2 months ago
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cartesian Therapeutics stock?
Cartesian Therapeutics (RNAC) has a market cap of $325M as of July 18, 2025.
What is the P/E ratio for Cartesian Therapeutics stock?
The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of July 18, 2025.
Does Cartesian Therapeutics stock pay dividends?
No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Cartesian Therapeutics dividend payment date?
Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) does not currently have a Beta indicator.